AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announces that following a strategic review by executive management, the Company is sharpening its focused investment on its most important assets. These include its three clinical-stage active immunotherapy programs, two of which are in ongoing pharma collaborations, and its most promising small molecule programs targeting NLRP3 and Tau. As a result, the Company will reduce its workforce by around 30% and extend its cash for operations to the end of Q3 2027.
– Strategic review by executive management yields increased pipeline focus and operational efficiencies with a workforce reduction of around 30%
– Increased emphasis on late-stage clinical development of active immunotherapy portfolio for Alzheimer’s and Parkinson’s diseases and progressing high value candidates enabling intracellular targeting
– Near term clinical milestones remain unchanged. Cash resources of CHF 127.1 million as of June 30, 2025, now provides cash for operations to the end of Q3 2027 not including potential payments from partnering